JP2020500563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500563A5 JP2020500563A5 JP2019551508A JP2019551508A JP2020500563A5 JP 2020500563 A5 JP2020500563 A5 JP 2020500563A5 JP 2019551508 A JP2019551508 A JP 2019551508A JP 2019551508 A JP2019551508 A JP 2019551508A JP 2020500563 A5 JP2020500563 A5 JP 2020500563A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- drug
- cancer
- nucleic acid
- transcriptional activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 229940079593 drug Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 108091006106 transcriptional activators Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- YHOXIEXEPIIKMD-UHFFFAOYSA-N 9a-[(4-chlorophenyl)methyl]-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-2,9-dihydro-1h-fluoren-3-one Chemical compound C1C2=CC(O)=CC=C2C2=C(C=3C=CC(OCCN4CCCCC4)=CC=3)C(=O)CCC21CC1=CC=C(Cl)C=C1 YHOXIEXEPIIKMD-UHFFFAOYSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000003687 estradiol congener Substances 0.000 claims 2
- 229960002258 fulvestrant Drugs 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 230000003284 homeostatic effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096360A JP7392043B2 (ja) | 2016-12-12 | 2022-06-15 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433183P | 2016-12-12 | 2016-12-12 | |
| US62/433,183 | 2016-12-12 | ||
| PCT/US2017/065597 WO2018111763A1 (en) | 2016-12-12 | 2017-12-11 | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096360A Division JP7392043B2 (ja) | 2016-12-12 | 2022-06-15 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500563A JP2020500563A (ja) | 2020-01-16 |
| JP2020500563A5 true JP2020500563A5 (enExample) | 2021-07-29 |
| JP7091357B2 JP7091357B2 (ja) | 2022-06-27 |
Family
ID=62559136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551508A Active JP7091357B2 (ja) | 2016-12-12 | 2017-12-11 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
| JP2022096360A Active JP7392043B2 (ja) | 2016-12-12 | 2022-06-15 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096360A Active JP7392043B2 (ja) | 2016-12-12 | 2022-06-15 | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11408005B2 (enExample) |
| EP (1) | EP3551197B1 (enExample) |
| JP (2) | JP7091357B2 (enExample) |
| CN (1) | CN110291200B (enExample) |
| AU (1) | AU2017375630B2 (enExample) |
| CA (1) | CA3045665A1 (enExample) |
| MX (1) | MX2019006631A (enExample) |
| WO (1) | WO2018111763A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| WO2018111763A1 (en) * | 2016-12-12 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| AU2019218729B2 (en) * | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| CA3105816A1 (en) * | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| KR20210063348A (ko) * | 2018-08-28 | 2021-06-01 | 이뮤노테크 바이오팜 씨오., 엘티디. | 개선된 치료용 t 세포 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| AU2020218446B2 (en) * | 2019-02-04 | 2023-05-25 | National University Corporation Ehime University | "CAR LIBRARY AND scFv MANUFACTURING METHOD |
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CA3140210A1 (en) * | 2019-03-13 | 2020-09-17 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers |
| WO2020219425A1 (en) * | 2019-04-25 | 2020-10-29 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias |
| CN114391021B (zh) * | 2019-06-21 | 2026-01-16 | 凯德药业股份有限公司 | TGF-β受体和使用方法 |
| US12702708B2 (en) | 2019-08-21 | 2026-08-11 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| CA3160614A1 (en) * | 2019-12-12 | 2021-06-17 | Marcela GUZMAN AYALA | Method and compositions for regulated armoring of cells |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| US20230242936A1 (en) * | 2020-05-14 | 2023-08-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Dual promoter systems |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| WO2021252358A1 (en) * | 2020-06-08 | 2021-12-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-cd171 chimeric antigen receptors |
| CN111848819A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
| US20230374104A1 (en) * | 2020-10-09 | 2023-11-23 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions comprising pd1 chimeric polypeptides |
| US20240043544A1 (en) * | 2020-12-08 | 2024-02-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| CN117177989A (zh) * | 2021-02-12 | 2023-12-05 | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 具有热休克蛋白90结合结构域的活性诱导型融合蛋白 |
| JP7894875B2 (ja) * | 2021-02-12 | 2026-07-24 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | 熱ショックタンパク質９０結合ドメインを有する活性誘導型融合タンパク質 |
| EP4323410A4 (en) * | 2021-04-15 | 2025-03-26 | The Regents of the University of Colorado, a body corporate | Compositions and methods for the preparation and use of cell-based immunotherapies against tumors |
| EP4341283A4 (en) * | 2021-05-14 | 2025-06-25 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Activity-inducible fusion proteins with a transcription factor and a heat shock protein 90 binding domain |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| CN116589585B (zh) * | 2021-12-29 | 2023-11-24 | 华道(上海)生物医药有限公司 | 一种抗IL13Ra2的纳米抗体及其应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| EP0650367A4 (en) | 1992-06-01 | 1998-04-15 | New England Medical Center Inc | BLOCKING OF INTERCELLULAR INTERACTIONS WITH CD43 CHEMICAL MOLECULES. |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| GB0015119D0 (en) * | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| AU2001270252B2 (en) | 2000-07-03 | 2007-02-08 | Catalent Pharma Solutions, Llc | Expression vectors |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| WO2002097050A2 (en) * | 2001-05-31 | 2002-12-05 | Novartis Ag | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| CA2481509A1 (en) | 2002-04-11 | 2003-10-23 | Suzanna Tatarewicz | Her-2 receptor tyrosine kinase molecules and uses thereof |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2004092338A2 (en) | 2003-04-11 | 2004-10-28 | Diadexus, Inc. | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| WO2005017102A2 (en) | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| EP1649020B1 (en) | 2003-07-21 | 2017-01-11 | MSD Italia S.r.l. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| US20070087346A1 (en) | 2003-10-24 | 2007-04-19 | Gennaro Ciliberto | Orthogonal gene switches |
| US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US7935510B2 (en) * | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| JP2009521474A (ja) | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| US8148129B2 (en) * | 2006-06-30 | 2012-04-03 | The Regents Of The University Of California | Generation of potent dominant negative transcriptional inhibitors |
| WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| JP5779090B2 (ja) | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| DK2346995T3 (en) | 2008-09-26 | 2019-02-11 | Tocagen Inc | GENETERIVE VECTORS AND CYTOSINDEAMINASES |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| US20100332417A1 (en) | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CN103502439B (zh) | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| PL2723773T3 (pl) | 2011-06-22 | 2018-07-31 | F.Hoffmann-La Roche Ag | Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| ITRM20120058A1 (it) | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| EP2817330B1 (en) | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| WO2013177533A1 (en) | 2012-05-25 | 2013-11-28 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| WO2013181440A1 (en) | 2012-05-30 | 2013-12-05 | Baylor College Of Medicine | Supercoiled minivectors as a tool for dna repair, alteration and replacement |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| US9792559B2 (en) | 2012-06-01 | 2017-10-17 | Nec Corporation | Switching system, line card, switch card, FDB learning method, FDB learning arbitration method and program |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| CN105339498A (zh) | 2013-03-07 | 2016-02-17 | 贝勒医学院 | 癌症中靶向cd138 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3858379A1 (en) | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| CN107074957B (zh) | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| JP7189019B2 (ja) | 2016-02-05 | 2022-12-13 | シティ・オブ・ホープ | 中枢神経系の癌の治療のための操作されたｔ細胞の投与 |
| WO2018111763A1 (en) | 2016-12-12 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
-
2017
- 2017-12-11 WO PCT/US2017/065597 patent/WO2018111763A1/en not_active Ceased
- 2017-12-11 MX MX2019006631A patent/MX2019006631A/es unknown
- 2017-12-11 EP EP17881828.2A patent/EP3551197B1/en active Active
- 2017-12-11 AU AU2017375630A patent/AU2017375630B2/en not_active Ceased
- 2017-12-11 CA CA3045665A patent/CA3045665A1/en active Pending
- 2017-12-11 JP JP2019551508A patent/JP7091357B2/ja active Active
- 2017-12-11 CN CN201780086283.8A patent/CN110291200B/zh active Active
- 2017-12-11 US US16/467,015 patent/US11408005B2/en active Active
-
2022
- 2022-06-15 JP JP2022096360A patent/JP7392043B2/ja active Active
- 2022-06-20 US US17/807,774 patent/US20220411805A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260078165A1 (en) | Processes for generating engineered cells and compositions thereof | |
| JP2021019589A5 (enExample) | ||
| Jacoby et al. | CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity | |
| US11896615B2 (en) | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators | |
| JP2024026186A (ja) | 操作されたｔ細胞の組成物を製造するための方法 | |
| CN110072533B (zh) | 选择性扩增γδT细胞群的方法及其组合物 | |
| JP2022130485A5 (enExample) | ||
| JP2025031794A (ja) | 遺伝子操作された細胞を調製するための方法および組成物 | |
| JP2017515464A5 (enExample) | ||
| US20170283807A1 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| JP2017513470A5 (enExample) | ||
| EP3703709A1 (en) | Molecular switch-mediated control of engineered cells | |
| JP2015525065A5 (enExample) | ||
| CN111246861A (zh) | 扩增表达重组受体的细胞的试剂 | |
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| WO2018205926A1 (zh) | 经修饰的t细胞、其制备方法及用途 | |
| RU2010125605A (ru) | Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме | |
| KR20240018454A (ko) | T 세포의 자극 및 형질도입 방법 | |
| WO2022063302A1 (zh) | 免疫细胞活性调节 | |
| CA3092794A1 (en) | Techniques for generating cell-based therapeutics using recombinant t cell receptor genes | |
| CN116970083A (zh) | 结合Trop2的抗体或Trop2抗原结合片段以及抗Trop2CAR和应用 | |
| JP2024544903A (ja) | Ｈｐｖ１６ ｅ７抗原を認識する結合タンパク質及びその使用 | |
| JP2023169422A (ja) | 結合ポリペプチドおよびそれを作製する方法 | |
| Xu et al. | Advances in the multi-omics landscape of follicular lymphoma | |
| JP2025522824A (ja) | 養子細胞療法におけるエフェクター細胞の耐久性及び有効性の増強 |